Product Description
Bortezomib is the first therapeutic proteasome inhibitor to be tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.It was originally synthesized in 1995 at Myogenics and was approved in the United States by the FDA for use in multiple myeloma in May 2003.
We provide the key intermediate (179324-87-9) and API, white powder solid,
the purity of Bortezomib intermediate (179324-87-9 ) is more than 99%(GC).
Top quality, more competitive price.
Annual capacity 140-160kg
NMR ,GC, IR,MOA,COA are available.The minimum order quantity is 50 g.
Packing size : special packing is offered.
![132112-67-5, Bicyclo[2.2.1]heptane-2,6-dicarbonitrile](https://www.pudeepharm.com/wp-content/uploads/2024/05/675.jpg)
![189253-72-3, (2-{2-[(3-aminopropyl)(methyl)amino]ethoxy}ethyl)dimethylamine](https://www.pudeepharm.com/wp-content/uploads/2024/05/723.jpg)
![835914-81-3, 4-[[4-[[6-[[1-Amino-8-hydroxy-7-[(4-nitro-2-sulfophenyl)azo]-4,6-disulfo-2-naphthalenyl]azo]-1-hydroxy-3,5-disulfo-2-naphthalenyl]azo]-2-chloro-6-sulfophenyl]azo]-4,5-dihydro-5-oxo-1-(4-sulfophenyl)-1H-pyrazole-3-carboxylic acid, lithium sodium salt](https://www.pudeepharm.com/wp-content/uploads/2024/05/813.jpg)
